Sana Biotechnology, Inc. (NASDAQ:SANA) Major Shareholder Ventures Fund V. Gener Flagship Sells 347,870 Shares

Sana Biotechnology, Inc. (NASDAQ:SANA – Get Rating) major shareholder Ventures Fund V. Gener Flagship sold 347,870 shares of the firm’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $6.57, for a total transaction of $2,285,505.90. Following the transaction, the insider now directly owns 1,447,791 shares in the company, valued at $9,511,986.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Sana Biotechnology Stock Performance

SANA stock traded up $0.04 during mid-day trading on Friday, hitting $6.28. The company had a trading volume of 1,094,503 shares, compared to its average volume of 1,201,326. The firm has a market cap of $1.20 billion, a PE ratio of -3.64 and a beta of 0.71. Sana Biotechnology, Inc. has a 12 month low of $2.99 and a 12 month high of $9.55. The stock’s fifty day moving average price is $4.98 and its two-hundred day moving average price is $4.51.

Sana Biotechnology (NASDAQ:SANA – Get Rating) last announced its quarterly earnings data on Thursday, March 16th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.01. Equities analysts anticipate that Sana Biotechnology, Inc. will post -1.49 earnings per share for the current year.

Hedge Funds Weigh In On Sana Biotechnology

Several large investors have recently modified their holdings of SANA. Principal Financial Group Inc. grew its stake in Sana Biotechnology by 6.5% during the first quarter. Principal Financial Group Inc. now owns 37,839 shares of the company’s stock valued at $124,000 after acquiring an additional 2,298 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Sana Biotechnology by 34.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,442 shares of the company’s stock valued at $45,000 after acquiring an additional 2,963 shares in the last quarter. Rhumbline Advisers grew its stake in Sana Biotechnology by 3.1% during the first quarter. Rhumbline Advisers now owns 142,592 shares of the company’s stock valued at $466,000 after acquiring an additional 4,260 shares in the last quarter. Swiss National Bank grew its stake in Sana Biotechnology by 7.9% in the 1st quarter. Swiss National Bank now owns 89,300 shares of the company’s stock worth $738,000 after buying an additional 6,500 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in Sana Biotechnology by 72.1% in the 1st quarter. American Century Companies Inc. now owns 18,465 shares of the company’s stock worth $57,000 after buying an additional 7,734 shares in the last quarter. Hedge funds and other institutional investors own 67.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. HC Wainwright assumed coverage on shares of Sana Biotechnology in a research report on Tuesday, May 2nd. They set a “neutral” rating on the stock. Bank of America lowered their price objective on shares of Sana Biotechnology from $13.00 to $11.00 in a research report on Friday, March 17th.

Sana Biotechnology Company Profile

(Get Rating)

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others.